Search Results for "vaccine, adult"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vaccine, adult. Results 241 to 250 of 295 total matches.
See also: MMR II
Lenacapavir (Sunlenca) for Multidrug-Resistant HIV
The Medical Letter on Drugs and Therapeutics • May 01, 2023 (Issue 1675)
drugs to treat multidrug-resistant HIV-1 infection
(MDR-HIV) in heavily treatment-experienced adults ...
The FDA has approved oral and injectable
formulations of the HIV-1 capsid inhibitor lenacapavir
(Sunlenca – Gilead) for use with other antiretroviral
drugs to treat multidrug-resistant HIV-1 infection
(MDR-HIV) in heavily treatment-experienced adults
whose current regimen is failing. Lenacapavir is the
third drug to be approved exclusively for treatment
of MDR-HIV; the intravenously administered CD4-directed antibody ibalizumab-uiyk (Trogarzo) and the
orally administered HIV-1 gp120-directed attachment
inhibitor fostemsavir (Rukobia) were approved earlier.
Med Lett Drugs Ther. 2023 May 1;65(1675):68-70 doi:10.58347/tml.2023.1675c | Show Introduction Hide Introduction
Bezlotoxumab (Zinplava) for Prevention of Recurrent Clostridium difficile Infection
The Medical Letter on Drugs and Therapeutics • Mar 27, 2017 (Issue 1517)
drug treatment to reduce recurrence
of Clostridium difficile infection (CDI) in adults with
CDI ...
The FDA has approved the fully human monoclonal
antibody bezlotoxumab (Zinplava – Merck) for use
with antibacterial drug treatment to reduce recurrence
of Clostridium difficile infection (CDI) in adults with
CDI at high risk for recurrence. It is the first drug to be
approved for this indication.
Expanded Table: Some Drugs for Inflammatory Bowel Disease (online only)
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023 (Issue 1680)
Expanded Table: Some Drugs for Inflammatory Bowel Disease
Drug Some Formulations Usual Adult ...
View the Table: Some Drugs for Inflammatory Bowel Disease
Med Lett Drugs Ther. 2023 Jul 10;65(1680):e115-9 doi:10.58347/tml.2023.1680d | Show Introduction Hide Introduction
Alemtuzumab (Campath) Off-Label for Relapsing Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Mar 09, 2009 (Issue 1307)
A 36-month study of 334 treatment-naïve adults with
early relapsing-remitting MS randomized 111 ...
Alemtuzumab (Campath), a genetically engineered, humanized monoclonal antibody currently approved to treat B-cell chronic lymphocytic leukemia (BCLL) and used off-label for induction therapy in solid organ transplants, is now also being tried off-label for treatment of relapsing multiple sclerosis (MS).
Ritlecitinib (Litfulo) for Severe Alopecia Areata
The Medical Letter on Drugs and Therapeutics • Nov 27, 2023 (Issue 1690)
alopecia areata; baricitinib (Olumiant), a JAK inhibitor, is approved only for use in adults.1 ...
The FDA has approved ritlecitinib (Litfulo – Pfizer), an
oral JAK and TEC kinase family inhibitor, for treatment
of severe alopecia areata in patients ≥12 years old.
Ritlecitinib is the second oral drug to be approved
in the US for treatment of severe alopecia areata;
baricitinib (Olumiant), a JAK inhibitor, is approved
only for use in adults.
Med Lett Drugs Ther. 2023 Nov 27;65(1690):185-6 doi:10.58347/tml.2023.1690a | Show Introduction Hide Introduction
Golimumab (Simponi) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Mar 31, 2014 (Issue 1439)
Formulations Adult Dosage Cost1
Infliximab – Remicade Mouse and Intravenous 100 mg vials Induction: 5 mg/kg ...
The FDA has approved golimumab (Simponi – Janssen),
a fully human monoclonal antibody specific for tumor necrosis
factor (TNF) alpha, for induction and maintenance
of remission in patients with moderate to severe ulcerative
colitis who do not respond to or cannot tolerate other
therapies or who require continuous treatment with corticosteroids.
Golimumab was approved earlier for treatment
of rheumatoid arthritis, psoriatic arthritis, and ankylosing
spondylitis. It is the third TNF inhibitor to be approved for
use in ulcerative colitis.
Ciltacabtagene Autoleucel (Carvykti) for Multiple Myeloma (online only)
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022 (Issue 1663)
product,
for treatment of relapsed or refractory
multiple myeloma in adults who received ≥4 prior
lines ...
The FDA has approved ciltacabtagene autoleucel
(Carvykti – Janssen), a B-cell maturation antigen
(BCMA)-directed genetically-modified cellular product,
for treatment of relapsed or refractory
multiple myeloma in adults who received ≥4 prior
lines of therapy, including a proteasome inhibitor,
an immunomodulatory drug, and an anti-CD38
monoclonal antibody. Carvykti is an individualized
cellular product prepared from the patient's own
T cells, which are genetically modified to express
chimeric antigen receptors (CAR) and then infused
back into the patient. Idecabtagene...
Dupilumab (Dupixent) for COPD
The Medical Letter on Drugs and Therapeutics • Jan 20, 2025 (Issue 1720)
) for add-on maintenance
treatment of adults with inadequately controlled
chronic obstructive pulmonary ...
The FDA has approved the subcutaneously injected
interleukin (IL)-4 receptor alpha antagonist dupilumab
(Dupixent – Sanofi/Regeneron) for add-on maintenance
treatment of adults with inadequately controlled
chronic obstructive pulmonary disease (COPD) and an
eosinophilic phenotype. Dupilumab is the first biologic
drug to be approved in the US for this indication. It has
been available for years for treatment of asthma, atopic
dermatitis, chronic rhinosinusitis with nasal polyps,
eosinophilic esophagitis, and prurigo nodularis.
Med Lett Drugs Ther. 2025 Jan 20;67(1720):11-3 doi:10.58347/tml.2025.1720c | Show Introduction Hide Introduction
Zimhi - A Higher-Dose Injectable Naloxone for Opioid Overdose
The Medical Letter on Drugs and Therapeutics • Apr 18, 2022 (Issue 1648)
. Approval was
based on the results of pharmacokinetic studies in
healthy adults showing that systemic ...
The FDA has approved a higher-dose injectable
formulation of the opioid antagonist naloxone
(Zimhi – Adamis) for emergency treatment of opioid
overdose. A single IM or SC injection of the new
formulation delivers 5 mg of naloxone; injectable
formulations that deliver 0.4 mg or 2 mg of the drug
have been available for years. Naloxone is also
available in intranasal formulations for the same
indication (see Table 1).
Mosunetuzumab (Lunsumio) for Follicular Lymphoma (online only)
The Medical Letter on Drugs and Therapeutics • Mar 06, 2023 (Issue 1671)
of relapsed or refractory follicular
lymphoma in adults who received ≥2 lines of systemic
therapy ...
Mosunetuzumab-axgb (Lunsumio – Genentech),
a bispecific CD20-directed CD3 T-cell engager,
has received accelerated approval from the FDA
for treatment of relapsed or refractory follicular
lymphoma in adults who received ≥2 lines of systemic
therapy. It is the first T-cell-engaging bispecific
antibody to be approved in the US for this indication.
Med Lett Drugs Ther. 2023 Mar 6;65(1671):e41-2 doi:10.58347/tml.2023.1671f | Show Introduction Hide Introduction